Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation (MASA-AF)

MASA (Metabolic-Atrial-Septal-Assessment) Score for Selecting Patients for Extended ECG Monitoring: A Prospective, Blinded, Single-Center Diagnostic Accuracy Cohort Study

The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.

Aperçu de l'étude

Statut

Pas encore de recrutement

Intervention / Traitement

Description détaillée

Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.

Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.

Pre-specified score (locked before enrollment): eGFR <60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.

Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.

Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.

Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.

Type d'étude

Observationnel

Inscription (Estimé)

700

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Dejan Munjiza, MD, MSc
  • Numéro de téléphone: +381608018437
  • E-mail: munjizad@gmail.com

Lieux d'étude

      • Belgrade, Serbie, 11000
        • Special Hospital for Cerebrovascular Diseases "Sveti Sava"

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.

La description

Inclusion Criteria:

  • Age 18 years or older
  • Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack)
  • Sinus rhythm on the admission 12-lead ECG
  • Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission

Exclusion Criteria:

  • Any previously documented atrial fibrillation or atrial flutter
  • Atrial fibrillation or atrial flutter on the admission ECG
  • Permanent pacemaker or implantable cardioverter-defibrillator
  • Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
  • Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
  • Expected duration of continuous ECG monitoring shorter than 24 hours

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
ICU patients with cardiovascular disease or stroke without known AF

Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay.

Calculation of the MASA score (range 0-8) from routinely collected data: eGFR <60 mL/min/1.73 m2 = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. A score >=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
Délai: From ICU admission to ICU discharge (up to 30 days)

Sensitivity and specificity (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader.

From ICU admission to ICU discharge (up to 30 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Positive and Negative Predictive Values of MASA Score >=5
Délai: From ICU admission to ICU discharge (up to 30 days)

Positive and negative predictive values (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring.

From ICU admission to ICU discharge (up to 30 days)
Discriminative Performance of the MASA Score
Délai: From ICU admission to ICU discharge (up to 30 days)

Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test.

From ICU admission to ICU discharge (up to 30 days)
Clinical Net Benefit of MASA-Guided Monitoring
Délai: From ICU admission to ICU discharge (up to 30 days)

Net benefit of selecting patients for extended ECG monitoring by MASA score >=5, assessed by decision curve analysis.

From ICU admission to ICU discharge (up to 30 days)
Number of Patients Monitored per Detected Atrial Fibrillation
Délai: From ICU admission to ICU discharge (up to 30 days)

Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score >=5.

From ICU admission to ICU discharge (up to 30 days)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Dejan Munjiza, MD, MSc, Special Hospital for Cerebrovascular Diseases "Sveti Sava"

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

30 décembre 2028

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

13 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the published results, together with the analysis code, will be made available.

Délai de partage IPD

After publication of the primary results, for at least 5 years.

Critères d'accès au partage IPD

Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner